SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses of $1.59M in Q1 FY2026
Q1 FY2026 other income / expenses was $1.59M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 1.58M USD
- Year-over-year change
- —
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.58M | — |
Other Income / Expenses vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.45M USD | -28.8% | — | 137.3% | |
| LTM Mar 2026 | $8.94M USD | -21.4% | -18.8% | 17.2% | |
| LTM Mar 2026 | $8.76M USD | -15.5% | — | 6.9% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $1.58M USD | — | — | — |
| LTM Mar 2026 | -$1.62M USD | -403.6% | — | 2.0% | |
| LTM Mar 2026 | -CHF 10.98M CHF | +56.5% | — | 2178.2% | |
| LTM Apr 2026 | -$14.55M USD | -327.2% | — | 5.0% | |
| LTM Jun 2026 | -$112.34M USD | -2575.6% | — | 18.3% | |
| LTM Sep 2026 | -$334.52M USD | -69.8% | — | 3.1% | |
| LTM Jun 2026 | -$445M USD | +6.3% | — | 8.4% | |
| Peer median (excluding SGP) | — | -28.8% | -18.8% | 8.4% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 612K |
| Gross Profit | (612K) |
| Gross Margin | — |
| Research & Development | 28.64M |
| Selling, General & Admin | 12.2M |
| Operating Expenses | 40.84M |
| Depreciation & Amortization | 612K |
| EBITDA | (39.26M) |
| EBITDA Margin | — |
| Operating Income | (41.45M) |
| Operating Margin | — |
| Interest Income | 3.11M |
| Interest Expense | 0 |
| Other Income / Expenses | 1.58M |
| Income Before Tax | (39.87M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (39.87M) |
| Net Margin | — |
| EPS (Basic) | (1.19) |
| EPS (Diluted) | (1.19) |
| Weighted Avg Shares | 33.43M |
| Weighted Avg Shares (Diluted) | 33.43M |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.